Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Mais filtros

Base de dados
Intervalo de ano de publicação
Orv Hetil ; 160(38): 1495-1502, 2019 Sep.
Artigo em Húngaro | MEDLINE | ID: mdl-31537098


A significant proportion of cancer patients reports a decline in their usual cognitive functions. This impairment may be the consequence of either the malignant disorder itself or the side-effect of the treatment. This impairment in cognitive skills was referred to with a sticky witty name as chemobrain or chemofog, reflecting on the old conception based on the assumption that solely the neurotoxic effect of chemotherapy was responsible for this kind of disturbances. However, today there is increasing evidence proving that such hypotheses can only partially explain the cognitive decline of cancer patients and cancer survivors. As a matter of fact, the cognitive impairment of cancer patients is a much more complex consequence of the malignant disorder than chemobrain or chemofog. Nowadays, this process is described as "cancer-related cognitive impairment" (CRCI). Orv Hetil. 2019; 160(38): 1495-1502.

Antineoplásicos/efeitos adversos , Transtornos Cognitivos/induzido quimicamente , Disfunção Cognitiva/induzido quimicamente , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Neoplasias/tratamento farmacológico , Antineoplásicos/uso terapêutico , Cognição , Transtornos Cognitivos/diagnóstico , Disfunção Cognitiva/diagnóstico , Humanos , Neoplasias/complicações